Reference : A novel heterozygous OPA3 mutation located in the mitochondrial target sequence resul...
Scientific journals : Article
Life sciences : Genetics & genetic processes
http://hdl.handle.net/10993/17213
A novel heterozygous OPA3 mutation located in the mitochondrial target sequence results in altered steady-state levels and fragmented mitochondrial network.
English
Grau, Tanja [> >]
Burbulla, Lena F. [> >]
Engl, Gertraud [> >]
Delettre, Cecile [> >]
Delprat, Benjamin [> >]
Oexle, Konrad [> >]
Leo-Kottler, Beate [> >]
Roscioli, Tony [> >]
Krüger, Rejko mailto [University of Luxembourg > Faculty of Science, Technology and Communication (FSTC) > Life Science Research Unit]
Rapaport, Doron [> >]
Wissinger, Bernd [> >]
Schimpf-Linzenbold, Simone [> >]
2013
Journal of medical genetics
50
12
848-58
Yes (verified by ORBilu)
0022-2593
1468-6244
England
[en] Adolescent ; Adult ; Aged ; Aged, 80 and over ; Cells, Cultured ; Cohort Studies ; DNA Mutational Analysis ; Female ; Fibroblasts/cytology ; Humans ; Male ; Middle Aged ; Mitochondria/genetics/metabolism/pathology ; Mutation/genetics ; Optic Atrophy, Autosomal Dominant/genetics ; Pedigree ; Proteins/genetics ; Mitochondria ; OPA3 ; Optic Atrophy
[en] BACKGROUND: Mutations in OPA3 have been reported in patients with autosomal dominant optic atrophy plus cataract and Costeff syndrome. Here, we report the results of a comprehensive study on OPA3 mutations, including the mutation spectrum and its prevalence in a large cohort of OPA1-negative autosomal dominant optic atrophy (ADOA) patients, the associated clinical phenotype and the functional characterisation of a newly identified OPA3 mutant. METHODS: Mutation analysis was carried out in a patient cohort of 121 independent ADOA patients. To characterise a novel OPA3 mutation, we analysed the mitochondrial import, steady-state levels and the mitochondrial localisation of the mutated protein in patients' fibroblasts. Furthermore, the morphology of mitochondria harbouring the mutated OPA3 was monitored. RESULTS: We identified four independent cases (representing families with multiple affected members) with OPA3 mutations. Besides the known p.Q105E mutation, we observed a novel insertion, c.10_11insCGCCCG/p.V3_G4insAP which is located in the mitochondrial presequence. Detailed functional analysis of mitochondria harbouring this novel mutation demonstrates a fragmented mitochondrial network with a decreased mitochondrial mass in patient fibroblasts. In addition, quantification of the OPA3 protein reveals decreased steady-state levels of the mutant protein compared with the native one. Comparison of the clinical phenotypes suggests that OPA3 mutations can additionally evoke hearing loss and by that extend the clinical manifestation of OPA3-associated optic atrophy. This finding is supported by expression analysis of OPA3 in murine cochlear tissue. CONCLUSIONS: In summary, our study provides new insights into the clinical spectrum and the pathogenesis of dominant optic atrophy caused by mutations in the OPA3 gene.
Luxembourg Centre for Systems Biomedicine (LCSB): Clinical & Experimental Neuroscience (Krüger Group)
http://hdl.handle.net/10993/17213

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Limited access
Grau2014.pdfPublisher postprint12.31 MBRequest a copy

Bookmark and Share SFX Query

All documents in ORBilu are protected by a user license.